We Built What the FDA Wouldn’t
Two Vials. Same NAD+. Different Lanes. They wouldn’t build it. So we did. The FDA refused to open a consumer pathway for injectable NAD+. The pharmaceutical industry refused to fund the trial that would have forced one. Neither moved because nobody could patent a molecule the body already makes. So the protocol stayed locked inside […]
